HUM

Business profile & competitive position

Humana Inc. is a Louisville, Kentucky-based health company classified under the Healthcare sector and the Medical - Healthcare Plans industry. It operates through two reportable segments: Insurance and CenterWell. The Insurance segment covers Medicare, state-based Medicaid, individual and employer plans, specialty benefits, military services, and a pharmacy benefit manager. CenterWell delivers pharmacy solutions, primary care, and home solutions. As of December 31, 2025, Humana served approximately 15.0 million members in medical benefit plans and roughly 4.7 million members in specialty products.

The company’s real margin and return figures suggest a capital-intensive, regulated business rather than a wide structural moat measured by profitability. Net margin sits at 0.9%, and return on equity is 6.9%. Those numbers are consistent with a health insurer that earns narrow underwriting spreads, manages large premium flows, and is heavily constrained by federal and state reimbursement rules. The stickier parts of the competitive position are scale, government-contract relationships, and the integrated-care footprint: CenterWell Primary Care operated 350 clinics, employed around 1,300 primary care providers, and served approximately 491,100 patients as of year-end 2025. In addition, approximately 2,260,900 members, or 15.1% of medical membership, were covered under shared-risk value-based arrangements, including 37.1% of total individual Medicare Advantage membership. That transition toward risk-based care may support stickier member relationships, but the 0.9% net margin confirms that pricing power is limited.

Financial posture

Humana currently carries a market capitalization of $46.3 billion and trades at a price-to-earnings ratio of 36.2. The stock’s current price is $385.265, with a 50-day exponential moving average of $368.83 and an RSI of 53.0. Net margin is 0.9% and ROE is 6.9%, while beta is 0.74, meaning the stock has historically moved with less volatility than the broader market.

The valuation gap between the P/E of 36.2 and the 0.9% net margin is striking. A high P/E on razor-thin current margins implies the market is pricing in either a recovery in profitability, long-term membership growth, or both. Government-dependent insurers can trade on adjusted earnings, normalized Medicare Advantage margins, or capital-return expectations rather than raw net margin, but the spread still stands out. The beta of 0.74 fits the defensive, contract-heavy business model. For comparison, ROE of 6.9% is below the typical hurdle many investors associate with a strong compounder, which reinforces that the investment case rests more on sector stability, scale, and execution than on outsized returns on equity.

Strategic priorities & outlook

Humana’s most recent 10-K outlines four operational priorities. The first is to operate an integrated care delivery model that combines quality care, high member engagement, and sophisticated data analytics. The second is to improve the consumer experience by simplifying interactions with Humana. The third is to engage members in clinical programs, and the fourth is to assist providers in transitioning from fee-for-service to value-based arrangements.

These priorities align with the numbers. The shift into value-based care is already reflected in membership: roughly 15.1% of medical membership, or 2,260,900 members, is under shared-risk arrangements, and 37.1% of total individual Medicare Advantage membership is in those models. The integrated-care push is also visible in the CenterWell build-out, with 350 primary care clinics and 491,100 patients as of year-end 2025. A notable concentration risk appears in Florida, where 14% of 2025 total premiums and services revenue came from individual Medicare Advantage contracts covering approximately 1.0 million members. That geographic and product concentration means execution in a single state can have an outsized impact on reported results and investor sentiment.

Macro & geopolitical exposure

As a Medical - Healthcare Plans company, Humana’s largest macro exposure is regulatory and reimbursement risk rather than trade or currency risk. The 10-K states that 83% of total premiums and services revenue came from contracts with the federal government in 2025. Medicare Advantage reimbursement rates set by the Centers for Medicare & Medicaid Services, Medicaid state budget decisions, and any changes to federal healthcare policy are therefore first-order variables for the stock.

Other relevant sector exposures include medical-cost trend inflation, prescription-drug pricing policy, and PBM regulation. Pharmacy costs flow through both the Insurance and CenterWell segments, so changes in drug pricing or rebate rules can affect margins. The digitization theme emphasized by recent sector coverage also matters: insurers are increasingly judged on administrative efficiency, digital enrollment, and data-driven care management. Supply-chain disruption is less central here than it is for manufacturers, but labor inflation in healthcare services can pressure the cost structure of owned assets such as primary care clinics and home-solutions operations.

Recent developments

Recent news flow has been broadly constructive. On August 24, 2026, Forbes published “As Health Insurers Gain Handle On Costs, Stocks Are Soaring Again,” reflecting a sector narrative that cost discipline is returning and margins may stabilize. The same day, Zacks ran “5 HMO Stocks to Watch Amid Steady Premium Flow, Increased Digitization,” placing Humana in a peer group benefiting from premium inflows and technology investment. Also on August 24, 2026, DefenseWorld reported that Barrow Hanley Mewhinney & Strauss LLC acquired 792,814 shares of Humana Inc. A day earlier, on August 23, 2026, DefenseWorld reported that Bank of Nova Scotia established a new position in the company. Taken together, the headlines point to renewed institutional interest in a Healthcare Plans sector that is being viewed more favorably as cost pressures ease.

Earnings behavior & post-earnings drift

Humana’s earnings track record over the last eight reported quarters is perfect: the company beat the consensus estimate in all eight quarters, for a 100% beat rate, with an average earnings surprise of 7.9%. Yet the post-earnings price reaction has not followed the obvious script. The average five-day move after earnings across those quarters is 0.06%, classified as flat drift.

The last four quarters demonstrate the disconnect clearly. On July 29, 2026, Humana reported EPS of $7.61 against an estimate of $7.27, a 4.7% positive surprise, but the stock rose only 0.34% the next day and fell 0.44% over the following five sessions. On April 29, 2026, EPS of $10.31 beat the $10.24 estimate by 0.7%; the stock dropped 2.75% the next day and gained 1.32% over five days. On February 11, 2026, a loss of $3.96 per share beat the estimated $4.00 loss by 1.0%, and the stock rallied 1.96% the next day and 8.61% over the next five days. The November 5, 2025 quarter was the starkest: actual EPS of $3.24 beat the $2.93 estimate by 10.6%, yet the stock fell 5.22% the next day and 9.23% over the following five sessions. This pattern is important for traders: beating the estimate has not reliably produced a directional follow-through. The market’s real expectation may already be priced in, or investors may be selling good headline numbers on concerns about forward guidance, Medicare Advantage rates, or medical-cost trends.

Humana is scheduled to report next on November 4, 2026, before the market open, with a current consensus EPS estimate of -$0.93.

For a deeper dive into how sell-side and institutional models are positioning around Humana ahead of the November 4, 2026 report, review the full institutional verdict on the ticker page.